Copper-dependent enzymes and DNA

Copper-dependent enzymes and DNA represent a complex therapeutic target profile primarily addressed by metallodrugs and copper-modulating agents. Copper-dependent enzymes, or cuproenzymes, include vital proteins such as superoxide dismutase (SOD), cytochrome c oxidase, and lysyl oxidase, which are essential for antioxidant defense, mitochondrial respiration, and connective tissue formation (UniProt). DNA acts as a critical molecular target for copper complexes, which can bind to the double helix through intercalation or electrostatic interactions (PubMed: PMC3510610). When these complexes are present, they often facilitate the production of reactive oxygen species (ROS) through Fenton-like reactions, leading to site-specific DNA strand breaks and subsequent cell death (PubChem). This dual targeting is particularly relevant in oncology, as cancer cells often exhibit altered copper metabolism and increased sensitivity to copper-induced oxidative stress (PubMed: 28533476). However, therapeutic intervention must be carefully calibrated to avoid systemic toxicity, as copper is an essential trace element for normal physiological function across multiple organ systems (NIH Office of Dietary Supplements).

Other names

Cuproenzymes and DNACopper-binding proteins and nucleic acidsCopper-dependent targets

Drugs targeting this system typically act by chelating copper to inhibit cuproenzyme activity or by forming copper-drug complexes that intercalate into DNA and generate reactive oxygen species (ROS) through Fenton-like chemistry, leading to apoptosis (PubMed: PMC3510610).